Search
GT 389-255
go.drugbank.com/drugs/DB05894ExperimentalIt is expected to block fat absorption with fewer side effects than currently marketed lipase inhibitors.
Dilmapimod
go.drugbank.com/drugs/DB12140InvestigationalPrevious p38 MAP-kinase inhibitors have been hindered in development by liver toxicity. Methotrexate (common treatment for RA patients) also has potential liver toxicity.}
NS-2359
go.drugbank.com/drugs/DB05805InvestigationalThis mode of action is expected to produce an optimal reduction in all disease symptoms and the possibility of an earlier onset of action compared to antidepressants already on the market. … NS2359 is a triple monoamine re-uptake inhibitor with a new, unique drug profile expected to yield important benefits compared to existing treatments of depression.
Lifitegrast
go.drugbank.com/drugs/DB11611ApprovedInvestigationalIt has shown to protect the corneal surface and alleviate the symptoms of dry eye syndrome with fast onset of action and well tolerated profile in both local and systemic setting [A18805].
Nitroxoline
go.drugbank.com/drugs/DB01422ExperimentalIt is a hydroxyquinoline derivative unrelated to other classes of drugs.[A179251] Nitroxoline is active against bacterial gyrases.
Synonyms: 5-NOK